Mineralys Therapeutics, Inc.

Overview

Compare with another stock.

• TickerMLYS on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersRadnor, Pennsylvania¹
• Business address150 N. Radnor Chester Road, Suite F200, Radnor, Pa²
• Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that we are developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA).³ From its latest annual report

Corporate structure

Mineralys Therapeutics, Inc. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Mineralys Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

We maintain our corporate offices at 150 N. Radnor Chester Road, Suite F200, Radnor, PA 19087 under a virtual office lease. We lease our corporate and other office premises under monthly rental agreements with terms of twelve months or less at a nominal cost. We consider our current office space adequate for our current operations.

Item 2 of the 10-K filed Mar 12, 2026.³

Leadership

Who has led Mineralys Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerJon Congleton Feb 9, 2023 to now⁹

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerAdam Levy named Jun 13, 2022²³

Timeline

1. Aug 11, 20268-K Results of operations; Executive or director change²⁴
2. Jun 3, 20268-K Entered a material agreement; New debt or obligation²⁵
3. Jun 3, 20268-K Other events²⁶
4. May 22, 20268-K Shareholder vote²⁷
5. May 6, 20268-K Results of operations²⁸
6. Mar 12, 20268-K Results of operations²⁹
7. Mar 9, 20268-K Regulation FD disclosure; Other events³⁰
8. Jan 6, 20268-K Regulation FD disclosure; Other events³¹
9. Nov 10, 20258-K Results of operations³²
10. Sep 3, 20258-K Other events³³
11. Sep 2, 20258-K Other events³⁴
12. Aug 12, 20258-K Results of operations³⁵
13. Feb 9, 2023New chief executive Jon Congleton becomes CEO⁹

Calendar

Coming up

1. Nov 9, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.52) a share, on Nov 10, 2025.³⁶

When it reported results

1. Aug 11, 2026Reported quarterly or annual results²⁴
2. May 6, 2026Reported quarterly or annual results²⁸
3. Mar 12, 2026Reported quarterly or annual results²⁹
4. Nov 10, 2025Reported quarterly or annual results³²
5. Aug 12, 2025Reported quarterly or annual results³⁵
6. May 12, 2025Reported quarterly or annual results³⁷
7. Feb 12, 2025Reported quarterly or annual results³⁸
8. Nov 12, 2024Reported quarterly or annual results³⁹

Drug trials and FDA: recently

1. Dec 30, 2025Phase 3 trial completed Phase 3 trial of lorundrostat in Hypertension: primary completion Dec 30, 2025, no results posted yet (ClinicalTrials.gov NCT05968430).⁴⁰
2. Dec 17, 2025Phase 2 trial completed Phase 2 trial of Lorundrostat in Obstructive Sleep Apnea: primary completion Dec 17, 2025, no results posted yet (ClinicalTrials.gov NCT06785454).⁴¹
3. Feb 27, 2025Phase 2 trial completed Phase 2 trial in Chronic Kidney Disease: primary completion Feb 27, 2025, results posted Jun 3, 2026 (ClinicalTrials.gov NCT06150924).⁴²

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

400 filings to the SEC since October 2021: 4 annual reports, 11 quarterly reports, 46 major events, 176 insider forms, 23 large holders, 1 private raises, 139 other. The latest 20:

1. Oct 13, 2026144 EDGAR
2. Oct 2, 20264 EDGAR
3. Sep 30, 2026144 EDGAR
4. Sep 24, 20264 EDGAR
5. Sep 22, 2026144 EDGAR
6. Sep 22, 20264 EDGAR
7. Sep 21, 2026144 EDGAR
8. Sep 17, 2026144 EDGAR
9. Sep 17, 20264 EDGAR
10. Sep 15, 2026144 EDGAR
11. Sep 14, 2026144 EDGAR
12. Sep 9, 2026144 EDGAR
13. Aug 25, 20264 EDGAR
14. Aug 21, 2026144 EDGAR
15. Aug 17, 2026144 EDGAR
16. Aug 13, 2026144 EDGAR
17. Aug 12, 20264 EDGAR
18. Aug 12, 20263 EDGAR
19. Aug 12, 20264 EDGAR
20. Aug 11, 202610-Q EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

108 open-market trades by officers, directors and large owners since October 2021: 18 buys and 90 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• FMR LLCSCHEDULE 13G/A, 2 filings Feb 5, 2026 to Aug 6, 2026⁴³
• Catalys Pacific Fund, LPSCHEDULE 13G/A, 4 filings Feb 13, 2024 to Feb 13, 2026⁴⁴
• BlackRockSCHEDULE 13G, 1 filing Jan 21, 2026⁴⁵
• RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13D/A, 4 filings Feb 24, 2023 to Sep 8, 2025⁴⁶
• Samsara BioCapital, L.P.SCHEDULE 13D/A, 4 filings Feb 24, 2023 to Sep 8, 2025⁴⁷
• Andera PartnersSCHEDULE 13G/A, 2 filings Feb 24, 2023 to Aug 14, 2025⁴⁸
• ADAMS STREET PARTNERS LLCSCHEDULE 13G/A, 2 filings Feb 14, 2024 to Feb 14, 2025⁴⁹
• HBM Healthcare Investments (Cayman) Ltd.SC 13G/A, 2 filings Feb 13, 2024 to Nov 13, 2024⁵⁰
• TCG Crossover GP II, LLCSC 13G/A, 2 filings Feb 15, 2024 to Nov 13, 2024⁵¹

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. Jun 1, 2022Raised $118 million in a private offering of equity²³ Form D: 23 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Mineralys Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARMineralys Therapeutics, Inc.¹
• CIK0001933414
• Employer ID (EIN)84-1966887³
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company³
• Incorporated inDelaware³
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address150 N. Radnor Chester Road, Suite F200, Radnor, PA¹
• Phone(888) 378-6240¹
• Shares outstanding88,406,885 as of Aug 3, 2026⁸
• Public float$676.0M as of Jun 30, 2025³
• AuditorErnst & Young LLP, Denver, Colorado PCAOB ID 42; no auditor attestation of internal control over financial reporting³
• On EDGAR sinceJun 13, 2022¹
• Filings400 in all: 4 (160), 144 (94), 8-K (46), 3 (16), 10-Q (11), 424B5 (6), SC 13G (5), SCHEDULE 13G/A (5)¹
  All 37 form types

  10-K (4), S-8 (4), SCHEDULE 13D/A (4), ARS (3), CORRESP (3), DEF 14A (3), DEFA14A (3), SC 13G/A (3), UPLOAD (3), DRS/A (2), DRSLTR (2), EFFECT (2), SC 13D (2), SC 13D/A (2), SCHEDULE 13G (2), SEC STAFF LETTER (2), 144/A (1), 424B4 (1), 8-A12B (1), CERT (1), D (1), DRS (1), S-1 (1), S-1/A (1), S-1MEF (1), S-3 (1), S-3/A (1), S-3ASR (1), S-3MEF (1)

• Latest filingsAnnual report (10-K) Mar 12, 2026
  Quarterly report (10-Q) Aug 11, 2026
  Proxy statement (DEF 14A) Apr 8, 2026
  Latest 8-K (8-K) Aug 11, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 12, 2026 (Section 12(b) of the Exchange Act).³

Risk factors and legal proceedings

The risks Mineralys Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 12, 2026: 73 risks under these headings, as written.³

• Risks Related to Our Limited Operating History, Financial Position, and Capital Requirements
• We have a limited operating history, have incurred significant operating losses since our inception, and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it.
• We will require substantial additional capital to finance our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our development programs, commercialization efforts, or other operations.
• Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.
• Risks Related to the Development and Regulatory Approval of Our Product Candidates
• We currently depend entirely on the success of lorundrostat, which is our only product candidate. If we are unable to obtain regulatory approval for, and ultimately commercialize, lorundrostat, or experience significant delays in doing so, our business will be materially harmed.
• Clinical and preclinical development involves a lengthy and expensive process with uncertain timelines and outcomes, and results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results. Lorundrostat may not achieve favorable results in our ongoing or future nonclinical studies or clinical trials or receive regulatory approval on a timely basis, if at all.
• Any difficulties or delays in the commencement or completion, or the termination or suspension, of our current or future clinical trials or preclinical studies could result in increased costs to us, delay or limit our ability to generate revenue, or adversely affect our commercial prospects.
• We may find it difficult to enroll participants in our future clinical trials. If we encounter difficulties or delays enrolling participants in our future clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
• Use of lorundrostat or any future product candidates could be associated with adverse side effects, adverse events, or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved label, or result in other significant negative consequences that could severely harm our business, prospects, operating results, and financial condition.
• We may not be successful in our efforts to investigate lorundrostat in additional indications. We may expend our limited resources to pursue, acquire, or license a new product candidate or a particular indication for lorundrostat and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
• We are conducting and intend to conduct some of our clinical trials for lorundrostat outside of the United States. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.

Legal proceedings

We are not currently a party to any material proceeding. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm, and other factors.

The opening of Item 3, Legal Proceedings.³